Alvarion Ltd

ALVR

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In AlloVir (ALVR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  AlloVir between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In AlloVir (ALVR) To Contact Him Directly To Discuss Their Options

NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.

NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AlloVir Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR). Investors who purchased AlloVir securities prior to March 22, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALVR.